SHANGHAI, June 19,
2024 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",
688373.SH), a multi-asset biopharmaceutical company focused
on the discovery and development of novel anti-infective therapies
for treating life-threatening infections, today announced 3 new
studies will be presented at the 7th World Bronchiectasis
Conference, taking place from July 4 - 6,
2024 in Dundee,
Scotland.
The presentations will showcase nonclinical data for MRX-5 and
MRX-8. MRX-5 is an oral investigational candidate for the treatment
of adults with nontuberculous mycobacteria (NTM) pulmonary
diseases. MRX-5 demonstrates potent antimicrobial activity against
Mycobacterium avium complex (MAC), the most common NTM
pathogen, as well as Mycobacterium abscessus complex (MABC),
the more difficult-to-treat NTM. MRX-5 is currently in Phase 1
clinical studies and topline results are expected in late
3Q2024.
MRX-8 is a novel compound in the polymyxin class. Nebulized
MRX-8 is developed for treating chronic Pseudomonas
aeruginosa lung infection in patients with bronchiectasis,
including infections caused by drug resistant isolates.
Presentations pertaining to MRX-5 and MRX-8:
Title: In Vitro And In Vivo Activity Of A
Novel Leucyl-Trna Synthetase Inhibitor Against Mycobacterium
Abscessus
Presenting Author: Regis Vilchez, MD, PhD (MicuRx)
Title: In Vitro Activity of Novel Leucyl-tRNA Synthetase
Inhibitor Against Mycobacterium Avium Complex
Presenting Author: Wen Wang,
PhD (MicuRx)
Title: In Vitro And In Vivo Activity Of A Novel
Antibiotic In The Polymyxin Class Against Pseudomonas
Aeruginosa
Presenting Author: Wen Wang, PhD (MicuRx)
About MicuRx
MicuRx is a biopharmaceutical company focusing on novel
therapeutics for infectious diseases. With global independent
intellectual property and competitiveness, we are committed to the
discovery, development, and commercialization of innovative drugs
for unmet medical needs. Since the company was founded in 2007,
MicuRx has adhered to the principle of "Better therapy through
superior medicine", focusing on the increasingly serious problem of
global antimicrobial resistance.
For more information, please visit our website at
www.micurx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/micurx-to-present-new-data-at-7th-world-bronchiectasis-conference-302176491.html
SOURCE MicuRx Pharmaceuticals